{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:26:33Z","timestamp":1792153593276,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ekir.2022.05.017","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:47:11Z","timestamp":1653526031000},"page":"1831-1841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria"],"prefix":"10.1016","volume":"7","author":[{"given":"Jonathan","family":"Barratt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Tumlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Aydemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore","family":"Pudota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hulin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"G\u00fchring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Appel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2022.05.017_bib1","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1681\/ASN.2005020134","article-title":"IgA nephropathy","volume":"16","author":"Barratt","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.05.017_bib2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.semnephrol.2004.01.001","article-title":"Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome","volume":"24","author":"D\u2019Amico","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ekir.2022.05.017_bib3","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","article-title":"Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population","volume":"27","author":"Le","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.05.017_bib4","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2022.05.017_bib5","first-page":"S20","article-title":"Current burden and probable increasing incidence of ESRD in China","volume":"74","author":"Zuo","year":"2010","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2022.05.017_bib6","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","article-title":"The emerging role of complement proteins as a target for therapy of IgA nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2022.05.017_bib7","doi-asserted-by":"crossref","first-page":"e91756","DOI":"10.1371\/journal.pone.0091756","article-title":"Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan","volume":"9","author":"Moriyama","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2022.05.017_bib8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2215\/CJN.07420716","article-title":"IgA nephropathy","volume":"12","author":"Rodrigues","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.05.017_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0002-9343(90)90300-3","article-title":"A\u00a0retrospective analysis of the natural history of primary IgA nephropathy worldwide","volume":"89","author":"Schena","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.ekir.2022.05.017_bib10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.05.017_bib11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00467-017-3699-z","article-title":"New insights into the pathogenesis of IgA nephropathy","volume":"33","author":"Yeo","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2022.05.017_bib12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/ki.2011.501","article-title":"An update on the pathogenesis and treatment of IgA nephropathy","volume":"81","author":"Boyd","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.05.017_bib13","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/ki.2015.252","article-title":"New developments in the genetics, pathogenesis, and therapy of IgA nephropathy","volume":"88","author":"Magistroni","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.05.017_bib14","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.ekir.2020.08.009","article-title":"Why target the gut to treat IgA nephropathy?","volume":"5","author":"Barratt","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2022.05.017_bib15","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/sj.ki.5000419","article-title":"Treatment of IgA nephropathy","volume":"69","author":"Barratt","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.05.017_bib16","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ekir.2022.05.017_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd1982","article-title":"An APRIL to remember: novel TNF ligands as therapeutic targets","volume":"5","author":"Dillon","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ekir.2022.05.017_bib18","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/art.30373","article-title":"Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ekir.2022.05.017_bib19","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2022.05.017_bib20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ekir.2022.05.017_bib21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, Phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2022.05.017_bib22","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/rheumatology\/keaa029","article-title":"Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study","volume":"59","author":"Morand","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2022.05.017_bib23","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s10157-013-0921-6","article-title":"Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy","volume":"18","author":"Suzuki","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2022.05.017_bib24","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A\u00a0randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"suppl 4","key":"10.1016\/j.ekir.2022.05.017_bib25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/nep.13453","article-title":"Update on treatment of immunoglobulin A nephropathy","volume":"23","author":"Zhang","year":"2018","journal-title":"Nephrol (Carlton)"},{"key":"10.1016\/j.ekir.2022.05.017_bib26","doi-asserted-by":"crossref","first-page":"715253","DOI":"10.3389\/fphar.2021.715253","article-title":"An update on targeted treatment of IgA nephropathy: an autoimmune perspective","volume":"12","author":"Huang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2022.05.017_bib27","article-title":"MO258 Safety, tolerability, pharmacokinetics and pharmacodynamics of VIS649, an APRIL-neutralizing IgG2 monoclonal antibody, in healthy volunteers: Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study","volume":"36","author":"Suzuki","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2022.05.017_bib28","article-title":"FC 040 Interim results of Phase 1 and 2 trials to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of BION-1301 in patients with IgA nephropathy","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl","key":"10.1016\/j.ekir.2022.05.017_bib29","first-page":"4B","article-title":"FR-PO1128 effects of blisibimod, a selective inhibitor of B-cell activating factor, in patients with IgA nephropathy","volume":"27","author":"Barratt","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.05.017_bib30","doi-asserted-by":"crossref","first-page":"rkz021","DOI":"10.1093\/rap\/rkz021","article-title":"Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme","volume":"3","author":"Gordon","year":"2019","journal-title":"Rheumatol Adv Pract"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922014152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922014152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T11:19:03Z","timestamp":1668856743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024922014152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2468024922014152"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2022.05.017","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2022.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}